Tuning the antigen density requirement for CAR T-cell activity

RG Majzner, SP Rietberg, E Sotillo, R Dong… - Cancer discovery, 2020 - AACR
RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, L Labanieh, JH Myklebust
Cancer discovery, 2020AACR
Insufficient reactivity against cells with low antigen density has emerged as an important
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that
modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is
dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel
(CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19-4-1BBζ) against antigen-low
tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based …
Abstract
Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel (CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19-4-1BBζ) against antigen-low tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based activation motifs (ITAM) in the CAR enables recognition of low-antigen-density cells, whereas ITAM deletions blunt signal and increase the antigen density threshold. Furthermore, replacement of the CD8 hinge-transmembrane (H/T) region of a 4-1BBζ CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunologic synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4-1BBζ-CARs with enhanced capacity to recognize antigen-low targets while retaining a superior capacity for persistence.
Significance
Optimal CAR T-cell activity is dependent on antigen density, which is variable in many cancers, including lymphoma and solid tumors. CD28ζ-CARs outperform 4-1BBζ-CARs when antigen density is low. However, 4-1BBζ-CARs can be reengineered to enhance activity against low-antigen-density tumors while maintaining their unique capacity for persistence.
This article is highlighted in the In This Issue feature, p. 627
AACR